Compare MGM Resorts International (MGM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs TG Therapeutics Inc — how do they compare? MGM Resorts International trades at $46.57 (market cap $11.86B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: MGM Resorts International is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MGM | TGTX | |
|---|---|---|
Market Cap | $11.86B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $59.06 |
52-Week Low | $30.72 | $26.39 |
Enterprise Value | $40.90B | $8.50B |
Dividend Yield | 0.03% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
